These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 22114986)
1. CHEK2 contribution to hereditary breast cancer in non-BRCA families. Desrichard A; Bidet Y; Uhrhammer N; Bignon YJ Breast Cancer Res; 2011; 13(6):R119. PubMed ID: 22114986 [TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
4. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709 [TBL] [Abstract][Full Text] [Related]
5. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994 [TBL] [Abstract][Full Text] [Related]
6. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance. Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080 [TBL] [Abstract][Full Text] [Related]
7. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations. Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467 [TBL] [Abstract][Full Text] [Related]
9. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692 [TBL] [Abstract][Full Text] [Related]
10. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women. Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089 [TBL] [Abstract][Full Text] [Related]
11. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998 [TBL] [Abstract][Full Text] [Related]
12. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]. Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209 [TBL] [Abstract][Full Text] [Related]
13. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N; Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780 [TBL] [Abstract][Full Text] [Related]
14. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713 [TBL] [Abstract][Full Text] [Related]
15. Limited relevance of the CHEK2 gene in hereditary breast cancer. Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295 [TBL] [Abstract][Full Text] [Related]
16. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families. Krivokuca A; Dobricic J; Brankovic-Magic M J BUON; 2013; 18(3):594-600. PubMed ID: 24065469 [TBL] [Abstract][Full Text] [Related]
17. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560 [TBL] [Abstract][Full Text] [Related]
18. The spectrum of mutations predisposing to familial breast cancer in Poland. Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Rusak B; Stempa K; Gronwald J; Szymiczek A; Bagherzadeh M; Jakubowska A; Dębniak T; Lener M; Rudnicka H; Szwiec M; Jarkiewicz-Tretyn J; Stawicka M; Domagała P; Narod SA; Lubiński J; Akbari MR; Int J Cancer; 2019 Dec; 145(12):3311-3320. PubMed ID: 31173646 [TBL] [Abstract][Full Text] [Related]
19. Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2. Nguyen-Dumont T; Jordheim LP; Michelon J; Forey N; McKay-Chopin S; ; Sinilnikova O; Le Calvez-Kelm F; Southey MC; Tavtigian SV; Lesueur F BMC Med Genomics; 2011 May; 4():39. PubMed ID: 21569354 [TBL] [Abstract][Full Text] [Related]
20. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]